ZA200101505B - Novel isoxazolinone antibacterial agents. - Google Patents

Novel isoxazolinone antibacterial agents. Download PDF

Info

Publication number
ZA200101505B
ZA200101505B ZA200101505A ZA200101505A ZA200101505B ZA 200101505 B ZA200101505 B ZA 200101505B ZA 200101505 A ZA200101505 A ZA 200101505A ZA 200101505 A ZA200101505 A ZA 200101505A ZA 200101505 B ZA200101505 B ZA 200101505B
Authority
ZA
South Africa
Prior art keywords
alkyl
optionally substituted
phenyl
alkoxy
halo
Prior art date
Application number
ZA200101505A
Inventor
Lawrence B Snyder
Zhizhen Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200101505B publication Critical patent/ZA200101505B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS
1S .
BACKGROUND OF THE INVENTION
1. Field of the Invention : 15 The present invention is directed toward new isoxazolinones, methods for their use, and processes for their production. The present ’ invention provides for a compound represented by the general formula 0} (op H
SNR
L or a pharmaceutically acceptable salt thereof wherein:
Ry is a) H, b) C4.g alkyl optionally substituted with one or more F, Cl, OH,
C1.g alkoxy, or C4_g acyloxy,
c) C3. cycloalkyl, or d) C4.g alkoxy;
L is oxygen or sulfur;
Ais a) k 0
Ra b)
Ry 3A
Re Rs c) a 5S-membered heteroaromatic moiety having one to three hetero atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is . bonded via a carbon atom and can additionally have a fused-on benzene or naphthyl ring, and wherein the : heteroaromatic moiety is optionally substituted with one to three Rg, d) a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three Ra, e) a B-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three Rg,
f) : Rit R : : aE
Rig K x 13, or e)
R11 Ry fod 1A
TX
Ria: wherein R; and Rj are each independently a) H, b) F, c) Cl, d) Br, e) C1. alkyl, f) NO,, 9 ) h) C14.s alkoxy, i) OH i) amino, k) cyano, or
D R2 and Rj taken together are -O(CH,),-O; wherein R, is a) H, b) C42 alkyl, c) F, or d) OH;
Rg is a) H, b) CF3, oo c) C1.3 alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) Rs and Rg taken together are a 5-, 6-, or 7-membered ring of the formula, 0= osc! h
SP f) in which D is S, O or NRgg in which Rgg is H or
C4.5 alkyl, or a) Rs and Rg taken together are -(CH,)i-, when Ry is an electron-withdrawing group;
Re and Ry at each occurrence are the same or different and are a) an electron-withdrawing group, b) H, ’ c) CFs, d) C4.3 alkyl optionally substituted with one halo, : e) phenyl, provided at least one of Rg and R; is an electron- withdrawing group, or f) Rg and Ry; taken together are a 5-, 6-, or 7-membered ring of the formula, iz ~c
Gm :
Uis a) CHo, b) 0,
C) Sor, d) NR1g;
Rig is a) Hor b) Cy. alkyl wherein Rg is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) NO, h) C1.¢ alkoxy, i) C1.¢ alkoxycarbonyl, i) C4 alkythio, k) Cypacyl, -NRy7R4s,
NOH : m) —C-Rg7 in which Rg is H or C4_g alkyl, n) C16 alkyl optionally substituted with OH, sulfamoyl, C4_5 alkoxy, Cq_5 acyl, or —NR17R 1s, 0) Co.g alkyl optionally substituted with one or two Rg, p) phenyl optionally substituted with one or two Ryg, q) a 5- or 6-membered saturated or unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two Rg, OF .
R17 and R4g at each occurrence are the same or different and are a) H, b) Cy alkyl,
Cc) Cs.g cycloalkyl, or d) R47 and R4g taken together with the nitrogen atom is a 5- or 6-membered saturated or unsaturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, O, and can in turn be optionally substituted with, including on the further nitrogen atom, C4_3 alkyl, formyl, a 5- or 6-membered heteroaromatic moiety 2 containing 1-3 O, N or S, —C~NRggRge in which Rgg and
Rgg are each independently hydrogen or C4_g alkyl, SOsRgg in which Rgq is H or C4_g alkyl, or C4_3 acyl optionally substituted with 1 or more F, Cl or OH; Rygis a) carboxyl, ‘ b) halo, c) -CN, d) mercapto, e) formyl, f) CFa, 9) NO,, h) = Cy alkoxy, i) C14.g alkoxycarbonyl, )) C1-g alkythio, k) C4. acyl, )) C4.s alkyl optionally substituted with OH, C4_s alkoxy, C4.5 acyl, or -NR47R4g,
m) phenyl, n) -C(=O)NRyR24, 0) -NRg7Rqg,
P) -N(Rg)(-SOzR3), q) -S05-NRygRo4, Or
Nn -S(=0)Ra;
Rog and R,4 at each occurrence are the same or different and are a) H, b) C1 alkyl, or
Cc) phenyl;
Rp is a) C414 alkyl, or b) phenyl optionally substituted with C44 alkyl; wherein Rg is : 15 a) carboxyl, b) halo, : : ¢ ON, d) mercapto, e) formyl, f) CF3, 9) NO, h) C1.g alkoxy, i) C1. alkoxycarbonyl,
I) C4. alkythio, k) C45 acyl, ) ~~ -NRy3Rp4, m) C4 alkyl optionally substituted with OH, C4_s alkoxy, C45 acyl, or -NRy3R»4,
: n) Co.g alkenylphenyl optionally substituted with one or two oo Ras, 0) phenyl optionally substituted with one or two Ros, p) a 5- or 6-membered saturated or unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two Rpg, or q) o
Rpz and Ry, at each occurrence are the same or different and are a) H, b) formyl, c) C14 alkyl, d) C44 acyl, 3 e) phenyl, : f) Cs. cycloalkyl, or g) R23 and Ry, taken together with the nitrogen atom is a 5- or 6-membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, O, and.can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C4_3 alkyl, or C4_5 acyl;
Ros is a) carboxyl, b) halo, 0) -CN, d) mercapto, e) formyl,
f) CFs, : a) NO,, h) C15 alkoxy, i) C4. alkoxycarbonyl, )] C1. alkythio, kK} ~~ Cqgacyl,
I) phenyl, m) C4 alkyl optionally substituted with OH, azido, C4_5 alkoxy,
C15 acyl, -NR3pR33 -SR34, -O-SO,R35, OF
Ru )—Hncoo. , n) -C(=O)NRzgRy7, 0) -NRz3R4,
P) -N(Rxg)}-SOzR2), qQ) -SO2-NRygRy7, or r -S(=0)iR22, s) -CH=N-Ryg, or t) -CH(OH)-SO3Rs4;
Rgpz is the same as defined above;
Ros and Rpy at each occurrence are the same or different and are a) H, b) Cyg alkyl, c) phenyl, or d) tolyl;
Rog is a) OH, b) benzyloxy, c) -NH-C(=0)-NH,,
d) -NH-C(=S)-NH,, or e) -NH-C(=NH)-NR3gR3g;
Rag and Rj at each occurrence are the same or different and are a) H, or b) C1-4 alkyl optionally substituted with phenyl or pyridyl;
Raq is a) H, or b) a sodium ion;
R32 and R33 at each occurrence are the same or different and are a) H, b) formyl, c) C14 alkyl, d) C44 acyl, e) phenyl, f) C35 cycloalkyl, ag) R32 and R33 taken together are a 5- or 6-membered saturated heterocyclic moiety having one to three atoms : selected from the group consisting of S, N, O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C4_3 alkyl, or C4_3 acy, h) -P(O)(OR37)(ORgg), or i) -S02-Rag;
Rag is
N-N NN N N ho a CL or Lo :
CHa CH; CHj
Rgjsis Cq.3 alkyl;
Rag is a) C14. alkoxycarbonyl, or b) carboxyl; ’ R37 and Rag at each occurrence are the same or different and are a) H, or b) C14.3 alkyl;
Rjgis a) methyl, b) phenyl, or 9) tolyl; wherein K is a) O, b) S, or c) NR40 in which Rg is hydrogen, formyl, C44 alkyl, C4_4 acyl, phenyl, Cg cycloalkyl, -P(O)(OR37)(OR3g) or =SO5-R3g in which R37, Rag and Rag are as defined above;
Ryp, R11, R12, R13, Ry4 and Ry5 at each occurrence are the same or different and are : a) H, b) formyl,
Cc) carboxyl, . d) C4 alkoxycarbonyl, e) C1.g alkyl, f) Cog alkenyl, wherein the substitutents (e) and (f) can be optionally substituted with
OH, halo, C_g alkoxyl, C4_g acyl, C4_g alkylthio or C4_g alkoxycarbonyl, or phenyl optionally substituted with halo, g) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF3, NO5, C44 alkyl, C4. alkoxy, C4.g acyl, C4_g alkylthio, or C1 ¢ alkoxycarbonyl;
h) ~~ -NR42R43, i) OR4g4, ) -S(=0)-Rys, kK) ~~ -SO2-N(Rgg)(Ra7), Or )] a radical of the following formulas:
Oe On OO rf Cont, 0 ruran— Rso 5 — —_ . Rs
Rs3 ww N— Rey—(CHt—N N— NENan _/ , 4, , or re”) . ;
R1g is the same as defined above;
Tis : a) oO, b) S, or *
Cc) SOy;
R42 and R43 at each occurrence are the same or different and are a) H, b) C3.5 cycloalkyl, c) phenyl, d) C4. acyl, e) C1.g alkyl optionally substituted with OH, C4_4 alkoxy which can be substituted with OH, a 5- or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, phenyl optionally substituted with OH, CF, halo, -NO,, C44 . ' 0 NN > alkoxy,-NR4gR4g, or o , f) “re
Res~CH— of 9)
VV N-(cgt— —/ :
Vis a) 0, b) CH,, or c) NRsg; :
R4g and Ryg at each occurrence are the same or different and are a) H, or b) C14 alkyl, : Rg4 is a) OH, b) C44 alkoxy, or ¢) -NRs7Rgs;
Rss is a) H, or b) C4.7 alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=0)-NHj, -CO5H, or -C(=NH)-NH,; :
Rsg is a) H, b) phenyl, or
Cc) C1. alkyl optionally substituted by OH;
Rs7 and Rgg at each occurrence are the same or different and are a H, b) Cys alkyl, c) C1.3 cycloalkyl, or d) phenyl;
Ryq is a) C+.g alkyl! optionally substituted with C4_.g alkoxy or C44 hydroxy, C3.g cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -NO,, CFj, halo, -CN, OH, C4_5 alkyl, C4_5 alkoxy, or
Cy.5 acyl, b)
Vo Ne(chgt— c) phenyl, or d) pyridyi; :
Rys is a) Cq.g alkyl, b) C,_1g alkenyl, wherein the substituents (a) and (b) can be optionally substituted with : C4. alkoxycarbonyl, or a 5-, 6-, or 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S,
N, and O, : c) an aromatic moiety having 6 to 10 carbon atoms, or d) a 5-, 6-, or 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF, -NO,,
C45 alkyl, C4 alkoxy, C1.¢ acyl, C1. akkyithio, or C45 : alkoxycarbonyl;
R46 and R47 at each occurrence are the same or different and are a) H, b) phenyl, c) C16 alkyl, or d) benzyl;
Rgp and Rg¢ at each occurrence are the same or different and are a) H, b) OH, c) C+. alkyl optionally substituted with -NR4gR4g in which
R4gand Ryg are as defined above, d) Rs and Rs4 taken together are =O;
Rsa is a) an aromatic moiety having 6 to 10 carbon atoms, b) a 5- or 6-membered aromatic optionally benzo-fused } heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) can in turn be optionally substituted with one or three -NO,, CF3, halo, -CN, OH, phenyl, C45 alkyl, C4.5 alkoxy, or C4_5 acyl, c) morpholinyl, d) OH, e) C46 alkoxy, f) -NR4gR4g in which R4qgand Ryg are as defined above, 9) -C(=0)-Rsp, or h)
O— a>
Rs3 is a) H, b) formyl,
Cc) Cq4 alkyl, d) C44 acyl, e) phenyl, f) Cag cycloalkyl, 9) -P(O)}ORg37)(ORgg), or h) -SO7R3g, in which R37, R3g and Rag are as defined above;
Rsgis a) morpholinyl, b) OH, or
Cc) C46 alkoxy; his1,2,0or3; iis 0,1,0r2; jis 0, or 1; kis 3, 4, or 5; : ris1,2,3,4,50r6; tis0,1,2,3,4,5,0r6; uis1or2; and
Qis a) hydrogen, b) halo,
Cc) NO, d) Ns, e) C4-Cg alkylthio,
Q
) CyCgalkyl—§—,
0 9) Cy-Cgalkyl—§—
Oo ’ : h) C1-Cg alkyl, i) C4-Cg alkoxy, )] formyl, k) C4-Cg alkyl—C—, 9 ) C4-Cg alkkyl—0-C—, m) -sulfamoyl (H,NSO,-), n) -NHOH, 0 o) CrCealkyl—C-0—
Q p) heteroaryl —C— in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, Nor S,
Q
: q) CeHs-C—, r amino, s) C4-Cg alkylamino-, t) di(C4-Cgalkylamino-, 0 u) (C4-Cg) alkyl—C-NRgoRg, in which Rgg and Rg are each independently hydrogen or C4-Cgq alkyl, v) OH, w) cyano,
X) hydroxy (C4-Cg alkyl), 9 y) C4-Cg alkyl—S-C—,
Q z) + NC—(CH,)—C— in whichris 1-6,
Q aa) CgHsCH,-O—-C—,
Q bb) CgHs-0O-C—,
Nes cc) Cy-Cealkyl—C— in which Rgy is hydrogen or Cy.¢ alkyl,
Q dd) RgsO—(CH,)16—C— in which Rg is hydrogen, C4. alkyl optionally substituted with one or more F, Cl, OH, C4_g alkoxy or C4_g acyloxy, C3.g cycloalkyl or C4_g alkoxy;
N-ORg,4 ee) H-C— inwhich Rg is hydrogen or Cq_g alkyl, ff) a substituted or unsubstituted Cg-C4q aryl moiety, gg) a substituted or unsubstituted monocyclic or bicyclic, } saturated or unsaturated, heterocyclic moiety having 1-3 atoms selected from O, N or S, said ring being bonded via a . ring carbon or nitrogen to the phenyl substituent, hh) a monocyclic or bicyclic substituted or unsubstituted heteroaromatic moiety having 1-3 hetero atoms selected from O, N or S, said ring being bonded via a ring carbon or nitrogen to the phenyl substituent and wherein the heteroaromatic moiety can additionally have a fused-on benzene or naphthalene ring; 20. the substituents for such p, q, ff, gg and hh moieties being selected from 1 or 2 of the following: 1) halo, 2) C4. alkyl, 3) NO,, 4) Na,
Q
. 5) C4-Cg alkyl —S—, 6) C.-Cs alkyl—S§— o 7) formyl,
Q
8) C4-Cg alkyl—C—,
Q
9) C4-Cg alkkyl—0-C— ) 0 10) heteroaryl—C— in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, Nor S, 0 . 11) CgHs—C—,
Q
12) -(C4-Ce) alkyl—C-NRgoRg4 in which Rgg and Rg are each independently hydrogen or C4-Cg alkyl, 13) OH, 14) hydroxy (C4-Cg alkyl),
Q
15) C4-Cgalkyl—S-C—,
Q
16) NC—(CH,), —O-C— in which ris 1-6,
Q
17) CgHsCH,—O-C—., 18) -CHy-Rgpin which Rgq is a) -OR3z in which Rj; is as defined above, b) -SR35 in which R35 is as defined above,
Cc) -NR32R33 in which Rg; and R33 are as defined above, or d) 9- or 6-membered heteroaromatic containing 1-4 O,
S or N atoms,
ORe 19) C;-Cgalkyl—C— in which Rey is as defined above, 20) cyano, 21) carboxyl, 22) CFs, } 0 23) C4-Cg alkyl—C-0—
Q
24) CgHs~0-C— in which the phenyl moiety may be optionally substituted by halo or (C4-Cg)alkyl, 2? 25) NRgoRz—C— in which Rg and Rg are as defined above, 0 Q 26) Rgy~NH-C— or Rg;~C-NH— in which Rg is a 5- or 6- membered aromatic heterocyclic group having 1-3 O, N or
S,
Q
27) CgHs(CH,);s—0-C—,
Q
28) RgsO—(CH,);s—0-C— in which Rgg is as defined above,
Q
29) SiRggRgoR191—0-CH,—C— in which Rgg, R1gp and Ryg4 are each independently C44 alkyl; or
Q and either R4 and Ry taken together form —O-CH,-O.
These derivatives are useful as antimicrobial agents which are effective against a number of human and veterinary pathogens, including gram positive bacteria such as multiply-resistant staphylococci,
streptococci, and enterococci, such as methicillin-resistant
Staphylococcus aureus or vancomycin-resistant Enterococcus faecium. 2. Description of the Prior Art
The literature contains a limited number of isoxazolinones used as pre-emergence herbicides. For example in U.S. Patent 4,065,463, 2- methyl-4-(trifluoromethyl-m-tolyl)-3-isoxazolin-5-one and 2-methyl-4- (chloro-m-tolyl)-3-isoxazolin-5-one are disclosed as being useful in preventing the growth of weeds which have a deleterious effect an crop production.
Od 04 [o] \ JS 7
AW : \ AW
U.S. Patent 4,000,155 discloses the related compound 1,2- dimethyl-4-(trifluoromethyl-m-tolyl)-3-pyrazolin-5-one for the same utility.
Q
' \ _ CHa
Nery
The applicant is not aware of any literature which discloses the use of these compounds as broad spectrum anti-bacterial agents. A different ring system is disclosed in WO 98/07708, which discusses the use of isoxazoline derivatives as anti-bacterial agents,
W, AN hog \'J ba where W is a substituted aryl or heteroaryl system and V is H, or C4-C4 alky! optionally substituted with F, Cl, OH, C4-C4 alkoxy, or acyloxy.
Oxazolidinones Il shown below are a well known class of orally active antibacterial agents. The prior art contains numerous references to ~ these compounds where Y and Z can include a wide variety of substituents. Specific substituted oxazolidinones are discussed in U.S.
Patent Nos. 4,705,799 and 5,523,403 (substituted phenyl 2- oxazolidinones), U.S. Patent Nos. 4,948,801; 5,254,577; and 5,130,316 (arylbenzene oxazolidinyl compounds), and European Patent Applications 0,697,412; 0,694,544, 0694,543; and 0,693,491 (5 to 9-membered heteroaryl substituted oxazolidinones). 0 “ON
TN n 0
Additionally, certain compounds containing a substituted furanone ring have been reported to possess antibiotic activity. WO 97/14690 discloses 6
EO
IO
L
— where T is hydroxy or NHC(O)C1-C4 alkyl, M and L are each independently hydrogen or fluoro, G and H are are each independently hydrogen or methyl, K-J is of the formula C=CH, CHCH2 or C(OH)CH2, is O, SO, SO2 or a substituted nitrogen, and Q-R is CH,-CH2 or CH=CH.
Other substituted furanones are discussed in U.S. Patent 5,708,169, WO 97/43280 and WO 97/10235.

Claims (1)

  1. LE WO 00/10566 PCT/US99/19265 CLAIMS We claim:
    1. A compound of the formula . 0 ' (op H ENR L 1 or a pharmaceutically acceptable salt thereof wherein: Ryis a) H, b) C1.g alkyl optionally substituted with one or more F, Cl, OH, C1-g alkoxy, or C4_g acyloxy, c) C3. cycloalkyl, or d) C4.g alkoxy; L is oxygen or sulfur; Ais a) 2 R3 b) Ry LAD c) a 5-membered heteroaromatic moiety having one to three hetero atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom and can additionally have a fused-on benzene or naphthyl ring, and wherein the heteroaromatic moiety is optionally substituted with one to three Rg, d) a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three Ry, e) a B-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three Rg, f) Rui Xe , or ¢)) R11 Ryy ed TAS TX Riz wherein Ry and Rj; are each independently a) H, b) F, c) Cl, d) Br, e) C15 alkyl, f) NO,, :
    : h) C1. alkoxy, . | | ) OH )] amino, . 5 k) cyano, or )) Rz and Rj taken together are -O(CHo)n-0; wherein Ry is : a) H, b) C1 alkyl, Cc) F, or d) OH; Rs is a) H, b) CF3, c) C1.3 alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) Rs and Rg taken together are a 5-, 6-, or 7-membered ring . of the formula, / 0g Jorn -/ ’ f) in which D is S, O or NRgg in which Rgg is H or
    C1. alkyl, or )) Rs and Rg taken together are -(CH,),-, when Ryis an electron-withdrawing group; Rg and Ry at each occurrence are the same or different and are a) an electron-withdrawing group, b) H,
    c) CF3, ’ d) C1.3 alkyl optionally substituted with one halo, e) phenyl, provided at least one of Rg and Ry; is an electron- withdrawing group, or f) Re and Ry taken together are a 5-, 6-, or 7-membered ring of the formula, is -c C Schalke Uis a) CHa, b) O, c) Sor, d) NR: Rig is a) H or b) C1.5 alkyl; wherein Rg is a) carboxyl, b) halo, ¢) -CN, d) mercapto, e) formyl, f) CFj, 9) NO, h) C4 alkoxy, )) C4.5 alkoxycarbonyl, )) C4. alkythio, k) Ci acyl,
    ) -NRyzR4g, NOH : oo m) ~~ —C-Rg; in which Rgz is H or C45 alkyl, n) C16 alkyl optionally substituted with OH, sulfamoyl, C4_s alkoxy, C45 acyl, or -NR47R4g, 0) C,_g alkyl optionally substituted with one or two Ryg, p) phenyl optionally substituted with one or two Rig, q) a 5- or 6-membered saturated or unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of §, N, and O, optionally substituted with one or two Rg, or o} R17 and R4g at each occurrence are the same or different and are a) H, j b) C14 alkyl, c) Cs cycloalkyl, or d). R47 and Rqg taken together with the nitrogen atom is a 5- or 6-membered saturated or unsaturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, O, and can in turn be optionally substituted with, including on the further nitrogen atom, Cq3 alkyl, formyl, a 5- or 6-membered heteroaromatic moiety : 2 containing 1-3 O, N or S, —C—NRggRgs in which Rgg and Rag are each independently hydrogen or C1. alkyl, SO;Rgg in which Rgg is H or C4_g alkyl, or C4_5 acyl optionally substituted with 1 or more F, Cl or OH;
    Rig is a) carboxyl, b) halo, ¢) -CN, d) mercapto, e) formyl, f) CFs, 9) NOz h) C45 alkoxy, i) C1. alkoxycarbonyl, i) C4. alkythio, k} Cspacyl, )) C1.6 alkyl optionally substituted with OH, C4_s alkoxy, Cis acyl, or -NR¢7R 4s, m) phenyl, n) -C(=0)NRygR54, : 0) -NR¢7Rqs, P) -N(R20)(-SOzR22), q) -SO2-NRygR»4, OF Nn -S(EO)R2; R20 and Ry4 at each occurrence are the same or different and are a) H, b) C1. alkyl, or Cc) phenyl; Rapjis a) C44 alkyl, or b) phenyl! optionally substituted with C4_4 alkyl;
    wherein Rg is a) carboxyl, b) halo, Cc) -CN, d) mercapto, e) formyl, f) CF 9) NO,, h) C,.s alkoxy, i) C1.g alkoxycarbonyl, ) C1. alkythio, k) C4 acyl, ) -NR23R24, m) Cy alkyl optionally substituted with OH, C1.5 alkoxy, C4.5 acyl, or -NRy3R54, n) C,.g alkenylphenyl optionally substituted with one or two Ras, o) phenyl optionally substituted with one or two R2s, P) a 5- or 6-membered saturated or unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two Ras, or q) Lo} Rpg and Ry, at each occurrence are the same or different and are a) H, b) formyl,
    c) C14 alkyl, d) Cygqacyl, e) phenyl, f) Cs_g cycloalkyl, or g) R23 and Ry4 taken together with the nitrogen atom is a 5- or 6-membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of §, N, O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C4_3 alkyl, or C4.3 acyl; Ros is a) carboxyl, b) halo, Cc) -CN, d) mercapto, e) formyl, f) CFj, 9) NO, h) Cy alkoxy, i) C1. alkoxycarbonyl, i) Cg alkythio, kK} Cigacyl ) phenyl, m) C4 alkyl optionally substituted with OH, azido, C4.5 alkoxy,
    C1.5 acyl, -NR3pR33 -SRgy4, -0-SO,R35, or Ru—(_)—coo. n) -C(=O)NRzgRz7, 0) -NRa3Ras
    BE a. - 144 - P) -N(Rge)(-SO2Rpy), q) -S05-NRygRo7, or nN -S(=O)Ry, Ss) -CH=N-Ryg, or t) -CH(OH)-SO3R3; Rog is the same as defined above; Ros and Ry7 at each occurrence are the same or different and are a) H, b) C1. alkyl, Cc) phenyl, or d) tolyl; Rog is a) OH, b) benzyloxy, c) -NH-C(=0)-NH,, d) -NH-C(=S)-NH,, or e) -NH-C(=NH)-NRygR3g; : Rag and Rj3q at each occurrence are the same or different and are a) H, or b) C14 alkyl optionally substituted with phenyl or pyridyl; R31 is a) H, or b) a sodium ion; R32 and Rj3 at each occurrence are the same or different and are a) H, b) formyl, c) C14 alkyl, d) C14 acyl, ~e) phenyi,
    f) Cag cycloalkyl,
    9) R32 and R33 taken together are a 5- or 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C4_3 alkyl, or C4_3 acyl,
    h) ~~ -P(O)(OR37)(OR3g), or i) -S0,-Rgg;
    Raq is C3 ane, CO.
    N > (CH3)C” “g ’ N Lor N ; CHs CHa CH Ras is Cq.3 alkyl; Rag is a) C4. alkoxycarbonyl, or b) carboxyl; Rgyand Rag at each occurrence are the same or different and are a) H, or b) Cyzalkyl; Rag is a) methyl, b) phenyl, or c) tolyl; wherein K is a) 0, b) S, or Cc) NR4o in which R4q is hydrogen, formyl, C4_4 alkyl, C4_4 acyl, phenyl, C3_¢ cycloalkyl, -P(O)(OR37)(OR3g) or -S05-R3g in which R37, Rag and Rg are as defined above;
    R10, R11, R12, R13 R44 and Rs at each occurrence are the same or different and are a) H, b) formyl, : x) ¢) carboxyl, d) C4. alkoxycarbonyl, e) C1.g alkyl, f) C,.g alkenyl, wherein the substitutents (e) and (f) can be optionally substituted with OH, halo, C4_g alkoxyl, C4_g acyl, C4 alkylthio or C4 alkoxycarbonyl, or - phenyl optionally substituted with halo, : 9) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF3, NO, Cg alkyl, C4. alkoxy, C1. acyl, C4 alkylthio, or Cis alkoxycarbonyl; h) ~~ -NRjs2Rg3, i) ORy4, I) -S(=0);-R4s. k) -SO2-N(R46)(Ray), or J) a radical of the following formulas: om Ge OO = cont ° ara Nie Fos = , Rsq , Rs3 WARE Rer—(CHt~N Ne Nan
    ~~. pe R1g is the same as defined above:
    Tis : a oO, b) S,or Cc) SO,; Ryo and R43 at each occurrence are the same or different and are a) H, b) C3. cycloalkyl, c) phenyl, d) Cigacyl, e) C.g alkyl optionally substituted with OH, C,_g alkoxy which can be substituted with OH, a 5- or 6- membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, phenyl optionally substituted with OH, CF3, halo, -NO,, C4_4 OX GC alkoxy,-NR4gR4g, OF o , n *\-Re Res-CH— of a) { h—(ongt— Vis a) 0, b) CHo, or c) NRgg; Rag and R4g at each occurrence are the same or different and are a) H, or b) C44 alkyl,
    Rs4 is a) OH, b) C1.4 alkoxy, or ¢) -NRs7Rsg; ; 5 Rssis a) H, or . b) C4.7 alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=0)-NH,, -CO,H, or -C(=NH)-NH; Rsgis a) H, b) phenyl, or c) C1. alkyl optionally substituted by OH; : Rs7 and Rsg at each occurrence are the same or different and are a) H, b) Cy.5alkyl, c) C14.3 cycloalkyl, or : d) phenyl; : Raq is a) C4. alkyl optionally substituted with C4_g alkoxy or C46 hydroxy, C3_g cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -NO,, CFj3, halo, -CN, OH, C4_5 alkyl, C1_5 alkoxy, or
    C1.5 acyl, b) VN (oHpt— —/ ’ Cc) phenyl, or d) pyridyl; : Rus is a) Cyqgalkyl, b) C.16 alkenyl, : wherein the substituents (a) and (b) can be optionally substituted with
    C1.s alkoxycarbonyl, or a 5-, 6-, or 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, Cc) an aromatic moiety having 6 to 10 carbon atoms, or d) a 5-, 6-, or 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF3, -NO,, C16 alkyl, C46 alkoxy, C4_¢ acyl, C4 alkylthio, or Cis 16 alkoxycarbonyl; R46 and R47 at each occurrence are the same or different and are a) H, b) phenyl, Cc) C46 alkyl, or d) benzyl; Rso and Rg4 at each occurrence are the same or different and are a) H, b) OH, c) C1.6 alkyl optionally substituted with -NR4gR 4g in which Rag and Ryg are as defined above, d) Rs and Rg4 taken together are =O; Rso is a) an aromatic moiety having 6 to 10 carbon atoms,
    '
    b) a 5- or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) can in turn be optionally substituted with one or three -NO,, CF3, halo, -CN, OH, phenyl, Cis alkyl, C4_g alkoxy, or C4_5 acyl, c) morpholinyl, . d) OH, e) Cyg alkoxy, f) -NR4gR4g in which R4g and Rg are as defined above, g) -C(=0)-Rsg, or h) 0" XX Jo Rs3 is a) H, b) formyl, c) C14 alkyl, d) C14 acyl, e) phenyl, f) Cs. cycloalkyl, g) -P(0)(OR37)(OR3g), or h) -SO2R3g, in which R37, Rag and Raq are as defined above: Rsg is a) morpholinyl, b) OH, or c) C4. alkoxy; his 1, 2, or 3; iis 0,1, 0r2;
    jis 0,0r1; kis 3, 4, or 5; ris1,2,3,4,50r6; tis0,1,2,3,4,5,0r6; wuis1or2; and Qis a) hydrogen, b) halo, c) NO,, d) Ns, e) C4-Cg alkylthio, : Q f) C,-Cg alkyl—S§—, 0 9) CyCealkyl—§— oS h) C4-Cg alkyl, i) C4-Cg alkoxy, J) formyl, Q kK) C,-Cg alkyl—C—, o h C4-Cg alkyl—0-C—, m) -sulfamoyl (H,NSO,-), n) -NHOH, 0 0) CyCealkyl—C-0— Q p) heteroaryl —C— in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, Nor S,
    PCT/US99/19265
    Q q) CgHs—C—, BB r) amino, S) C4-Cg alkylamino, t) di(C4-Cg alkyl)amino-, Q u) (C4-Cg) alkyl—C-NRggRg4 in which Rgg and Rg1 are each independently hydrogen or C4-Cg alkyl, v) OH, w) cyano, X) hydroxy (C4-Cg alkyl), 0 y) C,-Cg alkyl—-S-C—, 2 z) NC—(CH,),—C~— in which ris 1-6, Q aa) CeHsCH,-O—C— ) ) 0 bb) CgHs-O-C—, Noes cc) Cy-Cgalkyl—C— in which Rg is hydrogen or C4_5 alkyl, 0 16 dd) RgsO—(CH,)s.—C— in which Rs is hydrogen, C4.g alkyl optionally substituted with one or more F, CI, OH, Cis alkoxy or C4_g acyloxy, C3 g cycloalkyl or C1.g alkoxy; N-ORg, ee) H-C— inwhich Rg, is hydrogen or Cy alkyl, ff) a substituted or unsubstituted Cg-C1q aryl moiety, gg) a substituted or unsubstituted monocyclic or bicyclic, saturated or unsaturated, heterocyclic moiety having 1-3 atoms selected from O, N or S, said ring being bonded via a } ring carbon or nitrogen to the phenyl substituent, hh) a monocyclic or bicyclic substituted or unsubstituted heteroaromatic moiety having 1-3 hetero atoms selected from O, N or S, said ring being bonded via a ring carbon or nitrogen to the phenyl substituent and wherein the heteroaromatic moiety can additionally have a fused-on benzene or naphthalene ring; the substituents for such p, q, ff, gg and hh moieties being selected from 1 or 2 of the following: 1) halo, 2) C46 alkyl, 3) NO,, 4 Ns, Q 5) C,-Cg alkyl —S—, 0 6) Ci-Cealkyl—§— . O ' 7) formyl, Q 8) C4-Cg alkyl—C—, 0 9) Cy-Csakyl—0-C—,
    0 . 10) heteroaryl—C— in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, Nor S, 0 11) CgHs—C—, 0 12) -(C4-Ce) alkyl—C-NRgoRg4 in which Rgg and Rg4 are each independently hydrogen or C4-Cg alkyl,
    PCT/US99/19265
    13) OH, . 14) hydroxy (C4-Cg alkyl), , 15) C4-Cgalkyl—S-C—, ? 16) NC—(CH,), —O-C— in which ris 1-6, Q 17) CgHsCH,—0O-C—, 18) -CH3-Rgg in which Rgq is a) -OR3; in which Rg; is as defined above, b) -SR3; in which Rg, is as defined above, ¢) -NR3;Rg33 in which Ry, and R33 are as defined above, or d) 5- or 6-membered heteroaromatic containing 1-4 O, S or N atoms, N _ORg, 19) C4-Cgalkyl—c— in which Rgy is as defined above, 20) cyano, 21) carboxyl, 22) CFs, 0 23) C.-Cg alkkyl—Cc-0— : 2 24) CgHs-0-C~ in which the phenyl moiety may be optionally substituted by halo or (C4-Cg)alkyl, Q 25) NRgoRs—C— in which Rgy and Rg are as defined above, 2 ? 26) Rgi~NH-C— or Rgs—~C-NH— in which Rg is a §- or 6- membered aromatic heterocyclic group having 1-3 O, N or S,
    PCT/US99/19265
    0 . 27) CgHs(CHy)4.6~0-C— ’ 9 28) RgsO—(CH,)1.5—0-C— in which Rgs is as defined above, 0 29) SiRggR100R101—0-CHy—C— in which Rgg, R100 and R101 are each independently C4 alkyl; or Q and either Ry and R; taken together form —O-CH,-O.
    2. A compound of claim 1 wherein A is R at y Ras in which Q, R and Rj are as defined in claim 1.
    3. A compound of the formula >) 0) 3 O ¢ OH x R3 ~Y ! mw © or a pharmaceutically acceptable salt thereof, in which R1 is H, C4_g alkyl optionally substituted with one or more F, Cl, OH, C4.g alkoxy, or C4_g acyloxy, C3.g cycloalkyl or C4_g alkoxy; Ry and R3 are each independently a) H,
    b) F c Cl d Br e) C1. alkyl, f) NO,, a h) C1. alkoxy, i) OH )] amino, or Kk) cyano; and Qis a) hydrogen, b) halo, c) NO,, : dN, e) C4-Cg alkylthio, 0 f) C,-Cg alkyl —S—, : 0 9) CiCealkyl—s—, 0] h) C4-Cg alkyl, i) C4-Cg alkoxy, )) formyl, Q k) C.-Cg alkyl—Cc—, Q 1) C,-Cg alkyl—0-C—, 0) m) C4-Cg alkkyl—C-0—.,
    0 i n) heteroaryl —C— in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, Nor S, Q 0) CgHs-C— , p) amino, qQ) C4-Cg alkylamino-, r) di(C4-Cg alkyl)amino-, 0 s) (C4-Ce) alkyl—C-NRgoRg1,in which Reso and Rg4 are each independently hydrogen or C4-Cg alkyl, t) OH, u) cyano, Vv) hydroxy (C4-Cg alkyl), Q : w) C,-Cg alkyl —S-C—, ? X) NC—(CH,), —O-C— in which ris 1-6, 0 y) CgHsCH;—0O-C—, 0 2) CeHs-O-C— , \ _ORg,4 aa) Cy-Cgalkyl—C— wherein Rg, is hydrogen or C4_g alkyl, 0 bb) RgsO-(CH,).s—C— in which Rgg is hydrogen, C,_g alkyl optionally substituted with one or more F, CI, OH, C4.g alkoxy or C4_g acyloxy, C34 cycloalkyl or C4_g alkoxy, N-ORg,4 cc) H-C— in which Rg, is as defined above,
    dd) JO Se ee) \s|Ny X ] ff) YY W= X aN SX ag)
    yy. NT X YY \'e M H hh) X vl : "N Ne ii) x N ~ N N Mm 1 I) x ZN Sw Mm 1} kk) X JY 7h N SV m Y
    I) : o N—N X mm) : Nx sn Ny N= nn) Y N Hd NX X, 00) NN ALN \ Rez in which Rg, is H or C44 alkyl, PP) s (2x | N-N qq) X NY N We Y, Ir) NX —N~ 5 \=|= Y 16 ss) No —N _N \A:N x ?
    PCT/US99/19265 t X EN —N \=4N Y 3 uu) Ss —\ N N—YX wv)
    N. AN KY X Hi ww) X a Zn N SV Y t] XX) X H [T% B v 2” , yy) ORg2 0 AS 0) zz) (CHa), / rg, (CHa)p 16 aaa) a diazinyl group optionally substituted with X and Y, bbb) a triazinyl group optionally substituted with X and Y, ccc) a quinolinyl group optionally substituted with X and Y, ddd) a quinoxalinyl group optionally substituted with X and , eee) a naphthyridinyl group optionally substituted with X and ,
    ff) + Aq (CHw 2" y hd 14 agg) 2 0 PN N a yy Res” “ieHi J hhh)
    af . N ZO hd , or ii) Res N Lo A B is an unsaturated 4-atom linker having one nitrogen and three carbons; : 10 Mis a) H, b) C4_g alkyl, Cc) C4_g cycloalkyl, d) -(CH2)mORegg, or e) -(CH,),NRgs7Rgs; Zis a) oO, b) Sor ()] NM; Wis a) CH, b) Nor
    Cc) S or O when Z is NM; X and Y are each independently a) hydrogen, b) halo, ¢ NO, d Ns e) C4 alkythio, ? f) C,-Cs alkyl —S—, 0 9) Ci-Ceakyl—s—, 0) h) C4-Cg alkyl, i) C,-Cg alkoxy, i) formyl, Q Kk) C4-Cs alkyl—C— : 0 )] C4-Cg alkyl—0-C— : Q m) heteroaryl—C~ in which heteroaryl is a 5- or 6-membered aromatic heterocyclic group having 1-3 hetero atoms selected from O, N or S, Q n) CgHs—C—, 0) amino, Pp) C1-Cg alkylamino-, q) di (C4-Cg alkyl)amino-,
    Q r -(C4-Cg) alkyl—C-NRggRg; in which Rg and Rg are each independently hydrogen or C4-Cg alkyl, s) OH, t) hydroxy (C4-Cg alkyl), 2 u) C4-Cs alkyl —S-C—, 2 )] NC—(CH,), —0-C— in which ris 1-6, 0 w) CeHsCH,—0O-C— , Q X) CegHs-0O-C—, \ _ORg, y) Cq-Cgalkyl—C— in which Rg, is as defined above, z) cyano, aa) carboxyl,
    bb). CFj, cc) mercapto, Q dd) C4-Cqalkyl—C-0-— Q ee) CgHs~0O-C— in which the phenyl moiety may be optionally substituted by halo or C4-Cg alkyl, Q ff) ~~ CgHs(CHy)1s—0O-C—, Q 99) RgsO—(CH,)..s—C— in which Rgs is as defined above, or Q hh) SiRggR1ggR191—0-CH,—C— in which Rgo. R100 and R101 are each independently C4_g alkyl; or Q and either Ry and Rj taken together form —-O-CH,-O;
    Rg2 is a) H, b) C4.g alkyl optionally substituted with one or more halos, or C) C1.g alkyl optionally substituted with one or more OH, or
    C1.g alkoxy; Eis a) NRgg, b) -S(=0); in which iis 0, 1 or 2, or C) oO; Regis a) H, b) Cys alkyl, c) -(CHy)q-aryl, or d) halo; Rggis Hor Cq4 alkyl; : : Rg7 and Rgg are each independently H or C4_4 alkyl, or NRg7Rgg taken together are ~(CHj)-; : Reg is a) H, b) C4. alkyl, Cc) ~(CHa)q-aryl, d) -CO5Rg4, e) CORagy, f) -C(=0)-(CHp)q-C(=O)Rgy, g) -S(=0),-C4 5 alkyl, h) -S(=0),-(CHp)q-aryl, or i) -(C=0);-Het in which jis 0 or 1;
    Zyis a) -CHs-, or b) -CH(R7o}-CHy; Zyis a) -05S-, by -O-, c) -S-, d) -SO-, or e) -N(Rzqp)~ Zjis a) S, b) SO, c) SO,, or d) oO; Aqis Hor CHg; Apis : a) H, b) OH-, c) CH3COo-, d) CHsz-, : e) CH30-, f) Ry20-CHy-C(O)-NH-, 9) Ry30-C(O)-NH-, h) ~~ Ry73-C(O)-NH-, i) (C41-Co)alkyl-O-C(0)-, or J) HO-CHoy; or A, and A, taken together are
    :
    a) Ra1 Le or b) O=; Re4 is H or CHs-; mis4or5; nis0, 1,2 3,4o0r5; yisOor 1; pis0,1,2 3, 40r5; wis 1,2or3; qis1,2,30r4; zisOor 1; Regs is a) R740C(R75)(R76)-C(O)-, b) ~~ Rz70C(0)-, ¢) Ryg(0), d) R79-SO,-, or e) Rgg-NH-C(0)-; Ryo is H or (C4-C3)alky!; R74 is a) R740C(R75)(R76)-C(O)-, b) R770-C(O)-, ¢) Ryg-CO)-, I A e) I SSL f) HzC-C(0)-(CH,),-C(0)-, 8) Ry9-SOo-, h) o) ° 7 oo i) Rgo-NH-C(O)-, Ryo is a) H, b) CHj, c) phenyl -CH,-, or : d) CH3C(O)- R73 is (C4-Cg)alkyl or phenyl; ’ R74 is H, CH3, phenyl-CH,- or CH3-C(O)-; Rys and Ryg are each independently H or CH3, or R75 and Ry taken together are ~CH,CHo-; R77 is (C4-C3)alkyl or phenyl; Rg is H, (C1-Cg)alkyl, ary-(CHa)p1, CIH,C, ClgHC, FH,C-, FoHC- or (C3-Cg)cycloalkyl; Rygis CHa; -CH,CI, -CH,CH=CH,, aryl or -CH,CN; Rgg is =(CH»),1-aryl where nis 0 or 1; Rgq is a) H,
    b) C1. alkyl optionally substituted with one or more OH, halo or CN, 0 -(CHg)q—aryl in which q is as defined above, or d) -(CHy)q—ORgs in which q is as defined above: Rep is a) C4.6 alkyl optionally substituted with one or more OH, halo or CN, b) -(CHp)q-aryl in which q is as defined above, or c) ~(CH3)q-ORg3 in which q is as defined above: Rgjis a) H, b) C16 alkyl, Cc) -(CHy)q-aryl in which q is as defined above: or d) -C(=0) Cg alkyl; and | : aryl is phenyl, pyridyl or naphthyl, said phenyl, pyridyl or naphthyl : moieties being optionally substituted by one or more halo, -CN, OH, SH, C4. alkoxy or C4 alkylthio. )
    4. A compound of the formula Rz o] & ~My IA ° or a pharmaceutically acceptable salt thereof, in which RyisH, C4_g alkyl optionally substituted with one or more F, Cl, OH, Cy _g alkoxy or C4_g acyloxy, Ca. cycloalkyl or C4_g alkoxy;
    PCT/US99/19265
    Rz and Rj are each independently H or F; or R, and R taken together ’ represent ou > Qis a) hydrogen, b) halo, c) Ns d) NO,, e) C4-Cg alkylthio, Q f) C4-Cg alkyl—s— . 0 9) C,-Cgakyl—S— (0) Hl h) C4-Cg alkyl, i) C4-Cg alkoxy, J) formyl, Q kK) C4-Cg alkyl—Cc— , Q 0) C-Ce alky-0-C— Q m) C4+-Ce alkyl-Cc-0— , n) (C4-Ce alkoxy),N-, 0) 5- or 6-membered heterocyclic containing 1-3 O, N or S and linked to the phenyl substituent via a carbon or nitrogen, said heterocycle moiety being optionally substituted by Reg, OH N p) C4-Cg alkyl—C
    PCT/US99/19265 q) phenyl optionally substituted by Rgg, or } r) 5- or 6-membered saturated or unsaturated heterocyclic containing 1-3 O, N or S and linked to the phenyl substituent via a carbon or nitrogen, said heterocycle moiety being optionally substituted by Rgg, and Reg is a) C4-Cg alkyl-OH, b) C4-Csalkyl—0-c—, oO Q c) CH3—c— C,-Cg alkyl—C—, Oo d) cyano, e) formyl, - ’ NOH f) H-C— ’ : Q a) C4-Cs alkyl-O-C— , 0 : h) SiRg4RasReg~0-C— in which Rgy, Rgs and Rgg are each 16 independently C4-Cg alkyl, Q 0 ) CHy—s— C;-Cgalkyl—S—, oO 0) 2 )] HC=CCH,0C—, Q k) CeHs~0-C— here the phenyl may be optionally substituted by halo, Q ) HO-CH,-C—, m) (C1-Cg alkyl)oN-,
    ‘ | PCT/US99/19265 n) C4-Cg alkyb-NH-, 0) amino. 9 : Pp) C4-Cgalkyl—S—, Q q) CeHsCH,O0C—, or rn Rgg—C— in which Rgg is phenyl, 5- or 6-membered heteroaryl containing 1-3 O, N or S and linked to the phenyl substituent via a ring carbon atom or 5- or 8-membered saturated or unsaturated heterocyclic containing 1-4 O, N or S and linked to the phenyl substituent via a ring carbon atom.
    5. A compound selected from the group consisting of the compounds of Examples 1-87 described in the specification.
    6. A pharmaceutical composition comprising a compound of Claim 1 in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
    7. Use of a compound of Claim 1 in the manufacture of a medicament for treating a bacterial infection in a mammal.
    8. A substance or composition for use in a method of treating a bacterial infection in a mammal, said substance or composition comprising a compound of Claim 1, and said method comprising administering to a mammal a therapeutically effective amount of said substance or composition. AMENDED SHEET
    ; PCT/US99/19265
    9. A compound according to Claim 1, Claim 3, or Claim 4, substantially as herein described and illustrated.
    10. A pharmaceutical composition according to Claim 6, substantially as herein described and illustrated.
    11. Use according to Claim 7, substantially as herein described and illustrated.
    12. A substance or composition for use in a method of treatment according to Claim 8, substantially as herein described and illustrated.
    13. A new compound, a new composition, new use of a compound as claimed in Claim 1 or of a pharmaceutically acceptable salt thereof, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
ZA200101505A 1998-08-24 2001-02-22 Novel isoxazolinone antibacterial agents. ZA200101505B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9757498P 1998-08-24 1998-08-24

Publications (1)

Publication Number Publication Date
ZA200101505B true ZA200101505B (en) 2002-02-22

Family

ID=22264103

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200101505A ZA200101505B (en) 1998-08-24 2001-02-22 Novel isoxazolinone antibacterial agents.

Country Status (22)

Country Link
EP (1) EP1107756A4 (en)
JP (1) JP2002523369A (en)
KR (1) KR20010072945A (en)
CN (1) CN1314813A (en)
AR (1) AR020250A1 (en)
AU (1) AU748750B2 (en)
BR (1) BR9913225A (en)
CA (1) CA2341271A1 (en)
CO (1) CO5160266A1 (en)
CZ (1) CZ2001669A3 (en)
HU (1) HUP0103433A3 (en)
ID (1) ID27690A (en)
IL (1) IL141542A0 (en)
NO (1) NO20010916L (en)
NZ (1) NZ509867A (en)
PE (1) PE20001063A1 (en)
PL (1) PL346267A1 (en)
TR (1) TR200100672T2 (en)
TW (1) TW572757B (en)
UY (1) UY25677A1 (en)
WO (1) WO2000010566A1 (en)
ZA (1) ZA200101505B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JP2002020366A (en) * 2000-07-05 2002-01-23 Sumitomo Seika Chem Co Ltd Method for producing alkylthiophenylacetic acid
PE20030044A1 (en) 2000-11-17 2003-02-09 Upjohn Co BICYCLE ISOXAZOLINONES OF FORMULA I
PE20020689A1 (en) 2000-11-17 2002-08-03 Upjohn Co OXAZOLIDINONES WITH A HETEROCYCLE OF 6 OR 7 MEMBERS UNITED WITH ANNULAR LINK TO BENZENE
US6861433B2 (en) 2000-12-15 2005-03-01 Pharmacia & Upjohn Company Oxazolidinone photoaffinity probes
EP1349853B1 (en) 2000-12-21 2006-03-08 Pharmacia & Upjohn Company LLC Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
ES2180456B1 (en) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. SUBSTITUTED ISOXAZOLS AND ITS USE AS ANTIBIOTICS.
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
US7022705B2 (en) 2001-10-25 2006-04-04 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
WO2004033449A1 (en) * 2002-10-10 2004-04-22 Pharmacia & Upjohn Company Llc Antimicrobial 1-aryl dihydropyridone compounds
WO2004069832A2 (en) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Antibacterial agents
CA2529347C (en) 2003-04-30 2011-09-06 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
CN101429170B (en) * 2003-06-03 2015-05-13 梅林塔医疗有限公司 Biaryl heterocyclic compounds preparation and uses
AR045690A1 (en) 2003-06-03 2005-11-09 Rib X Pharmaceuticals Inc HETEROCICLIC BIARIL COMPOUNDS AND METHODS TO PREPARE AND USE THE SAME
EP1664001A2 (en) * 2003-07-29 2006-06-07 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
DE10340485B4 (en) * 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Process for the preparation of oxazolidinone-quinolone hybrids
US7304050B2 (en) * 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
WO2005061468A1 (en) 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
US8158797B2 (en) 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
PT1709044E (en) 2003-12-18 2008-10-27 Morphochem Aktiengese Fur Komb Oxazolidinone-quinolone hybrid antibiotics
WO2005082900A2 (en) * 2004-01-28 2005-09-09 Pharmacia & Upjohn Company Llc Oxazolidinone amidoximes as antibacterial agents
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
AT503354B1 (en) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh METHOD FOR THE PRODUCTION OF 3,4-DISUBSTITUTED PHENYL ACETIC ACIDS, AND NEW INTERMEDIATE COMPOUNDS
JP4518066B2 (en) * 2006-10-25 2010-08-04 宇部興産株式会社 Dialkoxynitrile derivative and process for producing the same
CN110423610B (en) * 2019-08-29 2023-05-12 浙江理工大学 Fluorescent probe for detecting two-photon mercury ions and preparation method and use method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2045049A1 (en) * 1970-09-11 1972-03-23 Dr Karl Thomae GmbH, 7950 Biberach New Nitrofurandenvate and processes for their production
US4000155A (en) * 1975-12-11 1976-12-28 Eli Lilly And Company Herbicidal 2-methyl-4-phenyl-5-pyrazolinones[and isoxazolinones]
DK0673370T3 (en) * 1992-12-08 1998-09-07 Upjohn Co Tropon-substituted phenyloxazolidinones as antibacterial agents
WO1997010235A1 (en) * 1995-09-15 1997-03-20 Pharmacia & Upjohn Company 5-AMIDOMETHYL α, β-SATURATED AND -UNSATURATED 3-ARYL BUTYROLACTONE ANTIBACTERIAL AGENTS
GB9521508D0 (en) * 1995-10-20 1995-12-20 Zeneca Ltd Chemical compounds
EP0920421B1 (en) * 1996-08-21 2002-11-06 PHARMACIA & UPJOHN COMPANY Isoxazoline derivatives useful as antimicrobials

Also Published As

Publication number Publication date
CO5160266A1 (en) 2002-05-30
CN1314813A (en) 2001-09-26
EP1107756A4 (en) 2003-02-26
NZ509867A (en) 2003-08-29
UY25677A1 (en) 2001-08-27
AU748750B2 (en) 2002-06-13
PE20001063A1 (en) 2000-12-24
KR20010072945A (en) 2001-07-31
PL346267A1 (en) 2002-01-28
TW572757B (en) 2004-01-21
EP1107756A1 (en) 2001-06-20
AR020250A1 (en) 2002-05-02
HUP0103433A3 (en) 2002-08-28
WO2000010566A1 (en) 2000-03-02
JP2002523369A (en) 2002-07-30
CZ2001669A3 (en) 2001-08-15
NO20010916D0 (en) 2001-02-23
NO20010916L (en) 2001-04-10
HUP0103433A2 (en) 2002-01-28
AU5783399A (en) 2000-03-14
IL141542A0 (en) 2002-03-10
TR200100672T2 (en) 2001-07-23
CA2341271A1 (en) 2000-03-02
BR9913225A (en) 2001-05-22
ID27690A (en) 2001-04-19

Similar Documents

Publication Publication Date Title
ZA200101505B (en) Novel isoxazolinone antibacterial agents.
EP2379537B9 (en) Isoxazoline derivatives and their use as pesticide
EP2295402A3 (en) Antibacterial agents
CL2004000400A1 (en) COMPOUNDS DERIVED FROM PIRIDINE REPLACED WITH 1,3-OXAZOL AND ISOXAZOL, PHARMACEUTICAL COMPOSITION, PREPARATION PROCEDURE, USEFUL AS ANTIBACTERIAL AGENTS, ACTIVE AGAINST NEGATIVE GRAM BACTERIA.
CA2577758A1 (en) Gyrase inhibitors and uses thereof
EP2379544A1 (en) Isoxazolines derivatives and their use as pesticide
NO20092542L (en) Antibacterial quinoline derivatives
RU2005100516A (en) 2-UREIDO-6-HETEROARYL-3H-BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND / OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFORMATION
WO2003004509A3 (en) C12 modified erythromycin macrolides and ketolides having antibacterial activity
WO2003004098A8 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
RU2450015C2 (en) Aminothiazole derivatives and application thereof as antibacterial agents
NO20092539L (en) Antibacterial quinoline derivatives
CA2430967A1 (en) Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
CA2483875A1 (en) 6,11 bicyclic erythromycin derivatives
EP1167375A1 (en) Erythromycin derivatives
US20020091107A1 (en) Oxazolidinone antibacterial agents
WO2021030379A9 (en) Bicyclic heteroaryl compounds useful as irak4 inhibitors
US4740502A (en) Semisynthetic erythromycin antibiotics
BR9708929A (en) Compound pharmaceutical composition and processes for controlling bacterial infection in a mammal and for preparing macrolide compounds
NO20092547L (en) Antibacterial quinoline derivatives
NO20092536L (en) Antibacterial quinoline derivatives
KR102428718B1 (en) Novel compounds, preparation method thereof, and antibiotic composition comprising the same
NO20092540L (en) Antibacterial quinoline derivatives
NO20016221L (en) Diphosphate salt of a 4 "-substituted-9-deoxo-9A-aza-9A-homoerythromycin derivative and pharmaceutical preparation thereof
NO20092541L (en) Antibacterial quinoline derivatives